Clinical characteristics of T790M-positive lung adenocarcinoma after resistance to epidermal growth factor receptor-tyrosine kinase inhibitors with an emphasis on brain metastasis and survival

Joo, Jin Woo; Hong, Min Hee; Shim, Hyo Sup

doi:10.1016/j.lungcan.2018.04.013

Cited by 23 publications

(38 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Joo et al and Huang et al also reported that those with an EGFR exon 19 deletion were more likely to develop secondary T790M than those with EGFR L858R, as well as uncommon mutations in cohorts with a majority of patients (96% and 94%, respectively) treated with gefitinib or erlotinib. 46 prior study by Wu et al found that patients treated with firstline afatinib had a rate of secondary T790M mutation similar to that of second-line afatinib 13 . Those with an uncommon EGFR mutation tended to be less likely to develop a T790M mutation (64.3% for exon 19 deletion, 45.5% for L858R and 16.7% for uncommon EGFR mutation, p = 0.142).…”

Section: Discussionmentioning

confidence: 84%

“…and Huang et al . also reported that those with an EGFR exon 19 deletion were more likely to develop secondary T790M than those with EGFR L858R, as well as uncommon mutations in cohorts with a majority of patients (96% and 94%, respectively) treated with gefitinib or erlotinib . A prior study by Wu et al .…”

Section: Discussionmentioning

confidence: 86%

“…45 Longer duration of EGFR TKI use was recently reported to be associated with a secondary EGFR T790M mutation. 46 Huang et al also found that PFS of more than 11 months was associated with secondary EGFR T790M mutation with an AUC of 0.594. 47 Since post-progression use of EGFR TKI is not uncommon, we thought EGFR TKI duration may be more appropriate than EGFR TKI PFS for TKI exposure.…”

Section: Discussionmentioning

confidence: 96%

“…Longer duration of EGFR TKI use was recently reported to be associated with a secondary EGFR T790M mutation . Huang et al .…”

Section: Discussionmentioning

confidence: 99%

See 3 more Smart Citations

Clinical outcomes and secondary epidermal growth factor receptor (EGFR) T790M mutation among first‐line gefitinib, erlotinib and afatinib‐treated non‐small cell lung cancer patients with activating EGFR mutations

Lin

Chen

Liao

et al. 2019

Intl Journal of Cancer

View full text Add to dashboard Cite

Gefitinib, erlotinib and afatinib are approved for first‐line treatment of advanced non‐small cell lung cancer (NSCLC) bearing an activating epidermal growth factor receptor (EGFR) mutation. However, the clinical outcomes among the three EGFR tyrosine kinase inhibitors (TKIs) are still controversial. We aimed to evaluate clinical outcomes and secondary EGFR T790M mutation among the three EGFR TKIs. From May 2014 to January 2016, a total of 301 patients received treatment with gefitinib, erlotinib or afatinib, for first‐line treatment of advanced NSCLC with an activating EGFR mutation, based on their clinicians’ choice. The median overall survival (OS) was 37.0 months. Although the baseline characteristics of patients were unequal, progression‐free survival and OS did not differ among the 3 groups. Multivariate analysis found that gefitinib (adjusted odds ratio [aOR] 3.29, 95% confidence interval [CI], 1.15–9.46, p = 0.027), EGFR TKI treatment duration more than 13 months (aOR 3.16, 95% CI, 1.20–8.33, p = 0.020), male (aOR 3.25, 95% CI, 1.10–9.66, p = 0.034), initial liver metastasis (aOR 4.97, 95% CI 1.18–20.96, p = 0.029) and uncommon EGFR mutation (aOR 0.14, 95% CI, 0.02–0.97, compared to EGFR deletion 19, p = 0.047) were independent factors for secondary T790M mutation. In real‐world practice, choosing first line EGFR TKI based on the patients’ clinical characteristics yielded good clinical outcomes. First‐line gefitinib, longer EGFR TKI treatment duration, male, initial liver metastasis and uncommon EGFR mutations may be independent factors for secondary EGFR T790M mutation.

show abstract

Section: Discussionmentioning

confidence: 84%

Section: Discussionmentioning

confidence: 86%

Section: Discussionmentioning

confidence: 96%

“…Longer duration of EGFR TKI use was recently reported to be associated with a secondary EGFR T790M mutation . Huang et al .…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Clinical outcomes and secondary epidermal growth factor receptor (EGFR) T790M mutation among first‐line gefitinib, erlotinib and afatinib‐treated non‐small cell lung cancer patients with activating EGFR mutations

Lin

Chen

Liao

et al. 2019

Intl Journal of Cancer

View full text Add to dashboard Cite

show abstract

“…To date, mostly retrospective [31][32][33][34][35][36][37][38][39][40][41][42][43][44][45] and 2 prospective 46,47 Asian case series investigated clinical-pathologic characteristics of T790M mutant lung cancer. Only a few data are available in Caucasian patients, and none of these studies investigated clinical progression patterns related to T790M in detail.…”

Section: Introductionmentioning

confidence: 99%

Clinical Features and Progression Pattern of Acquired T790M-positive Compared With T790M-negative EGFR Mutant Non–small-cell Lung Cancer: Catching Tumor and Clinical Heterogeneity Over Time Through Liquid Biopsy

Maso

Roca

Pilotto

et al. 2020

Clinical Lung Cancer

View full text Add to dashboard Cite

Minichromosome maintenance proteins in lung adenocarcinoma: Clinical significance and therapeutic targets

et al. 2023

View full text Add to dashboard Cite

Lung cancer is the most common cause of cancer‐related death worldwide, accounting for 1.8 million deaths annually. Analysis of The Cancer Genome Atlas data showed that all members of the minichromosome maintenance (MCM) family (hexamers involved in DNA replication: MCM2‐MCM7) were upregulated in lung adenocarcinoma (LUAD) tissues. High expression of MCM4 (P = 0.0032), MCM5 (P = 0.0032), and MCM7 (P = 0.0110) significantly predicted 5‐year survival rates in patients with LUAD. Simurosertib (TAK‐931) significantly suppressed the proliferation of LUAD cells by inhibiting cell division cycle 7‐mediated MCM2 phosphorylation. This finding suggested that MCM2 might be a therapeutic target for LUAD. Moreover, analysis of the epigenetic regulation of MCM2 showed that miR‐139‐3p, miR‐378a‐5p, and miR‐2110 modulated MCM2 expression in LUAD cells. In patients with LUAD, understanding the role of these miRNAs may improve prognoses.

show abstract

Clinical characteristics of T790M-positive lung adenocarcinoma after resistance to epidermal growth factor receptor-tyrosine kinase inhibitors with an emphasis on brain metastasis and survival

Cited by 23 publications

References 27 publications

Clinical outcomes and secondary epidermal growth factor receptor (EGFR) T790M mutation among first‐line gefitinib, erlotinib and afatinib‐treated non‐small cell lung cancer patients with activating EGFR mutations

Clinical outcomes and secondary epidermal growth factor receptor (EGFR) T790M mutation among first‐line gefitinib, erlotinib and afatinib‐treated non‐small cell lung cancer patients with activating EGFR mutations

Clinical Features and Progression Pattern of Acquired T790M-positive Compared With T790M-negative EGFR Mutant Non–small-cell Lung Cancer: Catching Tumor and Clinical Heterogeneity Over Time Through Liquid Biopsy

Minichromosome maintenance proteins in lung adenocarcinoma: Clinical significance and therapeutic targets

Contact Info

Product

Resources

About